Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Key PointsViking Therapeutics will soon enter phase 3 trials with its weight loss pill candidate.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Saturday assorted links

1. Chris Blattman’s practical AI for academics. 2. Platypus Economics on red diesel. 3. Those new service sector jobs, Indian cricket edition. 4. Will AI make us more technocratic? 5.

More from Saturday 10 October →